CA3031737A1 - Efficacite d'un conjugue anticorps-medicament anti-hla-dr (hl243-cl2a-sn -38) dans le traitement des cancers hla-dr positifs - Google Patents

Efficacite d'un conjugue anticorps-medicament anti-hla-dr (hl243-cl2a-sn -38) dans le traitement des cancers hla-dr positifs Download PDF

Info

Publication number
CA3031737A1
CA3031737A1 CA3031737A CA3031737A CA3031737A1 CA 3031737 A1 CA3031737 A1 CA 3031737A1 CA 3031737 A CA3031737 A CA 3031737A CA 3031737 A CA3031737 A CA 3031737A CA 3031737 A1 CA3031737 A1 CA 3031737A1
Authority
CA
Canada
Prior art keywords
antibody
cancer
hla
antibodies
immunoconjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3031737A
Other languages
English (en)
Inventor
Serengulam V. Govindan
Thomas M. Cardillo
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/281,453 external-priority patent/US10130626B2/en
Priority claimed from US15/484,308 external-priority patent/US10058621B2/en
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of CA3031737A1 publication Critical patent/CA3031737A1/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des immunoconjugués thérapeutiques comprenant SN-38 fixé à un anticorps anti-HLA-DR ou à un fragment d'anticorps de liaison à l'antigène. L'immunoconjugué peut être administré à une dose comprise entre 3 mg/kg et 18 mg/kg, de préférence 4, 6, 8, 9, 12, 12, 16 ou 18 mg/kg, de préférence encore 8, 10 ou 12 mg/kg. Lorsqu'il est administré à des dosages et posologies spécifiés, l'immunoconjugué peut réduire la taille de tumeurs solides, réduire ou éliminer les métastases et est efficace pour traiter les cancers résistant aux thérapies standard, telles que la radiothérapie, la chimiothérapie ou l'immunothérapie. Les procédés et les compositions sont particulièrement utiles pour traiter l'AML, l'ALL ou le myélome multiple.
CA3031737A 2016-08-11 2017-08-04 Efficacite d'un conjugue anticorps-medicament anti-hla-dr (hl243-cl2a-sn -38) dans le traitement des cancers hla-dr positifs Pending CA3031737A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662373591P 2016-08-11 2016-08-11
US62/373,591 2016-08-11
US15/281,453 US10130626B2 (en) 2012-12-13 2016-09-30 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US15/281,453 2016-09-30
US201662428231P 2016-11-30 2016-11-30
US62/428,231 2016-11-30
US15/484,308 2017-04-11
US15/484,308 US10058621B2 (en) 2015-06-25 2017-04-11 Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
PCT/US2017/045516 WO2018031408A1 (fr) 2016-08-11 2017-08-04 Efficacité d'un conjugué anticorps-médicament anti-hla-dr (hl243-cl2a-sn -38) dans le traitement des cancers hla-dr positifs

Publications (1)

Publication Number Publication Date
CA3031737A1 true CA3031737A1 (fr) 2018-02-15

Family

ID=61163070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3031737A Pending CA3031737A1 (fr) 2016-08-11 2017-08-04 Efficacite d'un conjugue anticorps-medicament anti-hla-dr (hl243-cl2a-sn -38) dans le traitement des cancers hla-dr positifs

Country Status (4)

Country Link
EP (1) EP3496754A4 (fr)
CN (1) CN109562172B (fr)
CA (1) CA3031737A1 (fr)
WO (1) WO2018031408A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187074A1 (fr) * 2017-04-03 2018-10-11 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse
FR3072880A1 (fr) * 2017-10-30 2019-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Formulation liposomale et son utilisation en therapie anti-tumorale
TW202003047A (zh) * 2018-03-23 2020-01-16 美商西雅圖遺傳學公司 包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585491B2 (en) * 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
CN101171034B (zh) * 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
EP2550975A1 (fr) * 2011-07-29 2013-01-30 Sanofi Polythérapie pour le traitement de symptômes de malignités CD19+lymphocytes B comprenant un immunoconjugué anti-CD19 maytansinoïde et du rituximab
WO2013043800A1 (fr) * 2011-09-22 2013-03-28 Immunomedics, Inc. Anticorps anti-hla-dr inhibant les réactions immunitaires allogènes et xénogènes en cas de greffe d'organe
HRP20220399T1 (hr) * 2012-12-13 2022-05-13 Immunomedics, Inc. Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
US9107960B2 (en) * 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
CA2914438C (fr) * 2013-07-23 2022-06-14 Immunomedics, Inc. Immunoconjugues anticorps-sn-38 avec un lieur cl2a

Also Published As

Publication number Publication date
WO2018031408A1 (fr) 2018-02-15
EP3496754A4 (fr) 2020-04-15
EP3496754A1 (fr) 2019-06-19
CN109562172B (zh) 2022-08-16
CN109562172A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
US20240352147A1 (en) Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
AU2019250192B2 (en) Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10954305B2 (en) Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
US10918734B2 (en) Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
US10918721B2 (en) Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10709701B2 (en) Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10988539B2 (en) Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
CN109562172B (zh) 抗HLA-DR抗体药物缀合物IMMU-140(hL243-CL2A-SN-38)在HLA-DR阳性癌症中的功效
CA3043766A1 (fr) Therapie du cancer du poumon a petites cellules (cppc) avec un conjugue anticorps-medicament (cam) inhibiteur de la topoisomerase i ciblant trop-2
US20240148873A1 (en) Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2017180565A1 (fr) Polythérapie avec des anticorps anti-hla-dr et des inhibiteurs de kinase dans des cancers hématopoïétiques

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802